RISK OF OVERTREATMENT OF PATIENTS WITH ADRENAL INSUFFICIENCY:
CURRENT AND EMERGING ASPECTS

G. Mazziotti¹, A.M. Formenti², S. Frara³, E. Roca⁴, P. Mortini⁵, A. Berruti⁴, A. Giustina³.

¹Endocrinology Unit, ASST, Carlo Poma, Mantua, Italy; ²Department of Molecular and Translational Medicine, University of Brescia, Italy; ³Chair of Endocrinology, San Raffaele Vita-Salute University, Milan, Italy; ⁴Chair of Medical Oncology, University of Brescia, Italy; ⁵Chair of Neurosurgery, San Raffaele Vita-Salute University, Milan, Italy.

Short-title: AI overtreatment

Key-words: Adrenal insufficiency, cortisol, replacement, osteoporosis

Corresponding author:

Prof. Andrea Giustina, Chair of Endocrinology, San Raffaele Vita-Salute University, Milan, Italy

e-mail: a.giustina@libero.it
Abstract

The effects of long-term replacement therapy of adrenal insufficiency (AI) are still a matter of controversy. In fact, the established glucocorticoid replacement regimens do not completely mirror the endogenous hormonal production and the monitoring of AI treatment may be a challenge for the lack of reliable biochemical markers. Consequently, several AI patients may be exposed to relative glucocorticoid excess that, even if mild, may potentially lead to development of chronic complications, such as diabetes mellitus, dyslipidemia, hypertension and fragility fractures with consequent impaired QoL and increased mortality risk.

This review deals with the pathophysiological and clinical aspects concerning the over-replacement therapy of primary and secondary AI.
Introduction

Adrenal insufficiency (AI) is a severe and potentially life-threatening disease caused by a primary or secondary impairment of function of adrenocortical cells. Thomas Addison firstly described the clinical picture of the disease characterized by lassitude, fatigue, weight loss and skin hyperpigmentation associated with a “remarkable form of anaemia” attributed to a pathological condition of “supra-renal capsules” [1]. Before the availability of synthetic glucocorticoids, all patients with AI died within 5 years of diagnosis [2]. The outcome of disease greatly improved after availability of hydrocortisone [3], but the effects of long-term replacement therapy of AI are still a matter of controversy. In fact, one could argue that the long-term replacement therapy with glucocorticoids should have no negative effects due to its substitutive nature [4]. However, over the last years it has become evident that, even treated, AI continues to be associated with considerable morbidity, impaired quality of life (QoL) and reduced life expectancy [5]. Indeed, the established glucocorticoid replacement regimens do not completely mirror the endogenous hormonal production and their monitoring is also made difficult by the lack of reliable biomarkers [6]. As a matter of fact, several AI patients may be exposed to mild glucocorticoid excess with potential development of complications, such as diabetes mellitus, dyslipidemia, hypertension and fragility fractures leading to impaired QoL and increased all-risk mortality. These aspects are particularly relevant when AI does coexist with other diseases, such as growth hormone (GH) deficiency (GHD), hypogonadism and neoplasia, which may have per se a significant impact on morbidity and life expectancy of patients [7, 8].

This review deals with the pathophysiological and clinical aspects of the risk of overreplacement therapy in patients with primary and secondary AI. Part of the review will be devoted to drug-induced AI as an emerging model of glucocorticoid over-replacement in the specific clinical context of hypogonadal patients with prostate cancer receiving abiraterone [9] and patients with adrenocortical carcinoma receiving mitotane [10]. Full text articles in the English
language were selected from a PubMed search spanning 1994-January 2017, for key-words including “adrenal insufficiency”, “cortisol replacement”, “glucocorticoid overtreatment”, “cardiovascular risk”, “osteoporosis”, “fractures”, “quality of life”, “mortality”. Reference lists in selected papers were also used to broaden the search.

**Physiology of the hypothalamic-pituitary-adrenal axis**

Adrenal glands secrete cortisol, aldosterone and androgens. Physiologically, the secretion of cortisol and androgens is under the dominant control of pituitary corticotropin (ACTH), whereas aldosterone is primarily regulated by the renin-angiotensin system. ACTH is synergistically synthesized and secreted in response to hypothalamic hormones corticotrophin-releasing hormone (CRH) and vasopressin (ADH), and in turn stimulates cortisol synthesis and release. ACTH has ultradian and circadian rhythmicity, with a nadir between 2400 and 0200 h, rising to peak on waking, and then gradually falling throughout the day, except small rises after eating [11]. Therefore, normal individuals have very low or undetectable levels of circulating cortisol at midnight; cortisol levels then increase overnight to peak early in the morning and then decline slowly throughout the day. Many stressors can break through this rhythm, particularly inflammatory or infective stress, severe hypotension and intense exercise.

Cortisol circulates in the blood mainly bound to a hepatic-derived cortisol binding globulin, with the approximately 5% free hormone being biologically active. Glucocorticoids exert their effects on responsive cells by binding to and activating a 90-kDa intracellular glucocorticoid receptor protein. The peripheral activity of cortisol may be influenced by polymorphism of glucocorticoid receptor [12]. Moreover, the cortisol availability to responsive cells is regulated by the enzyme 11β-hydroxysteroid dehydrogenase deputed to modulate in the target tissues the activation (i.e., transformation of cortisone in cortisol by type 1 enzyme) and inactivation (i.e., transformation of cortisol in cortisone by type 2 enzyme) of glucocorticoids [13].
States of hypo- and hyperadrenalism may impact on several neuroendocrine axes such as the hypothalamus-pituitary-gonadal axis as well as the GH-insulin-like growth factor-1 (IGF-1) axis which is suppressed in both adrenal insufficiency and hyperfunction [14, 15].

**Causes of AI**

*Primary AI*

Primary AI is the consequence of the destruction or impaired function of adrenocortical cells. In western countries and in Japan, the most common cause of primary AI is autoimmune [4, 16], whereas tuberculosis is still predominant in developing countries [4, 17]. Other causes of primary AI include bilateral adrenalectomy (a third line option in Cushing disease), drugs (e.g., ketoconazole, rifampicin, mitotane), non tubercular infections (e.g., histoplasmosis, cryptococcosis, paracoccidiomycosis), genetic diseases and metastatic and haemorragic disorders [4, 18]. Currently, primary AI is estimated to affect around 100,000 individuals in Europe [19, 20], with a prevalence ranging from 93 to 221 cases/million and incidence estimated at 4–6 cases per million per year [18].

Mitotane (1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane, o,p-DDD) is available for the treatment of adrenocortical carcinoma since decades [21] and it has a potent adrenolytic activity due to the o,p-DDD isomer [22]. Sterol O-acyltransferase-1 inhibition by mitotane leads to intracellular accumulation of toxic lipids which results in activation of the endoplasmic reticulum stress response and consequently results in reduced steroidogenesis and apoptosis of adrenal carcinoma cells [23]. Mitotane has an irreversible and preferable binding with both zona fasciculata and zona reticularis in adrenal cortex [24], whereas the zona glomerulosa is relatively spared by the cytotoxic effect of mitotane [21].

*Secondary AI*
AI may be secondary to ACTH deficiency due to pituitary and hypothalamic diseases including tumors, surgical hypophysectomy, head traumas, radiotherapy, autoimmune hypophysitis, empty sella [25]. Furthermore, AI may be caused by iatrogenic suppression of hypothalamus-pituitary-adrenal axis as a consequence of high-doses steroid treatment abruptly stopped [26] or as effect of chronic treatment with drugs targeting the nervous system, such as opioids [27, 28].

The prevalence of central hypoadrenalism is estimated around 125-280 per million with up to one-third of patients with pituitary disease presenting this condition [29].

**Adrenal Hyperplasia- Congenital**

Congenital adrenal hyperplasia is a group of genetic disorders characterized by impaired cortisol synthesis due to inactivating mutations of key enzymes in the steroidogenetic process. The incidence ranges from 1:10’000 to 1:20’000 births [30] with a higher prevalence in some ethnic groups (e.g. Alaskan Yupiks). The most common form of congenital adrenal hyperplasia is caused by mutations in *CYP21A2*, the gene encoding the adrenal steroid 21-hydroxylase enzyme [31]. This enzyme converts 17-hydroxyprogesterone to 11-deoxycortisol and progesterone to deoxycorticosterone, respective precursors for cortisol and aldosterone. Patients affected by the classical form of congenital adrenal hyperplasia caused by deficiency of 21-hydroxylase enzyme have deficiency of both cortisol and aldosterone. The cortisol synthetic block leads to ACTH stimulation of the adrenal cortex, with accumulation of cortisol precursors that are diverted to sex hormone biosynthesis resulting in prenatal virilization of girls and rapid somatic growth with early epiphyseal fusion in both sexes [31]. More rarely, congenital adrenal hyperplasia is caused by deficiency of P450c17 enzyme which sequentially catalyzes 17α-hydroxylase and 17,20-lyase reactions, which are essential for the production of glucocorticoids and sex steroids, respectively [32]. In the adrenal gland, the lack of P450c17 enzyme activity decreases androgen and cortisol synthesis and stimulate the secretion of ACTH. Increased ACTH in turn promotes adrenal
hyperplasia with excessive production of mineralocorticoids (11-deoxycorticosterone) upstream of 17α-hydroxylase and C17,20-lyase defect leading to development of hypertension and hypokalemia associated to sexual infantilism in males [32].

**Adrenal Hyperplasia- Acquired**

An emerging form of acquired adrenal hyperplasia is that induced by abiraterone in patients with prostate cancer. Abiraterone is a potent, selective, and irreversible inhibitor of 17α-hydroxylase and C17,20-lyase currently used in patients with prostate cancer resistant to conventional androgen deprivation therapy with GnRH agonists [33, 34]. As in the congenital form of adrenal hyperplasia, the inhibition of 17α-hydroxylase and C17,20-lyase by abiraterone is accompanied by androgen and cortisol insufficiency accompanied by excessive production of mineralocorticoids (11-deoxycorticosterone) upstream of enzymatic block. Other anti-androgen agents used in the treatment of advanced prostate cancer such as enzalutamide (which is commercially available) and other molecules still undergoing clinical development do not interfere with adrenal hormone synthesis [35, 36].

**Treatment options of AI: conventional and emerging therapeutic regimens**

AI could be theoretically treated with different types of glucocorticoids. Indeed, the European Adrenal Insufficiency Registry observational study showed a significant heterogeneity in the type, dose, frequency and timing of glucocorticoid replacement of primary and secondary AI in real-life clinical practice [37].

**Hydrocortisone and cortisone acetate.** In many countries hydrocortisone is available as 10 or 20 mg tablets or 2.5 mg pellets. In countries where hydrocortisone is not easily available, 25 mg tablets of cortisone acetate are used to replace AI. Cortisone acetate is a pro-hormone which needs to be converted in hydrocortisone via the hepatic 11β-hydroxysteroid dehydrogenase type 1. The
glucocorticoid activity of cortisone acetate is equivalent to 0.8 of hydrocortisone. Hydrocortisone has short half-life (approximately 90 minutes) [38] and multiple dosing is recommended to try mimicking physiological conditions. The first and largest dose is suggested to be given upon awakening, the next either in the early afternoon (2 h after lunch; two-dose regimen) or at lunch and afternoon (three dose regimen) [39,40], to avoid an overexposure to cortisol during the night when physiological cortisol secretion is barely detectable [41]. The absorption curve of cortisone acetate is less steep and delayed as compared to hydrocortisone favoring a longer half-life [42]. Therefore, cortisone acetate can be administered in two doses with the largest one in the morning and the smallest one in the early afternoon [40]. These therapeutic regimens are applied to all patients with AI regardless of being primary or secondary.

**Prednisone and dexamethasone.** Dexamethasone is readily absorbed after oral administration achieving peak plasma concentrations after one hour and the biological half-life is approximately 36-54 hours. Prednisone is a glucocorticoid prodrug that is converted by 11β-hydroxysteroid dehydrogenase in the liver into the active form, prednisolone. It is rapidly absorbed across gastrointestinal membrane and it shows a peak effect after 1-2 hours with a biological half-life of 18-36 hours.

Clinicians should remember that prednisone and dexamethasone have five and 30-50 fold greater glucocorticoid activity as compared to hydrocortisone, respectively. Prednisone exerts 80% of the mineralocorticoid activity of cortisol while dexamethasone has no mineralocorticoid activity. When long-acting glucocorticoids are used, one daily dose around 5 mg of prednisone and 0.5 mg of dexamethasone is sufficient to replace cortisol insufficiency [30, 40]. However, even when used at equivalent physiological doses, prednisone and dexamethasone may potentially cause unfavorable effects due to their long half-life not resembling the physiological daily curve of cortisol. The use of these glucocorticoids is different depending on the cause of AI.
New formulations of hydrocortisone

Dual-release hydrocortisone consists of an immediate-release coating surrounding an extended-release core [43]. When administered once daily upon awakening, dual-release hydrocortisone provides high levels of cortisol during the morning, followed by a gradual decrease throughout the day, thereby mimicking normal cortisol secretion more closely than conventional therapy [43].

Chronocort is another modified-release hydrocortisone formulation consisting of uniform multiparticulate beads which have an inert core, a hydrocortisone drug layer, and a delayed-release enteric outer coat that has a pH trigger of 6.8 allowing small bowel dissolution. This drug when administered twice-daily (i.e., 10 mg at 0700 h and 20 mg at 2300 h) approximated physiologic cortisol rhythm replacing the overnight rise in cortisol levels [44], which is not mimicked by conventional formulations and the dual-release hydrocortisone.

Primary AI

Patients with primary and secondary AI require lifelong glucocorticoid replacement. The current guidelines recommend using hydrocortisone or cortisone acetate to replace primary or secondary AI [25, 29, 30, 40], whereas other glucocorticoids are not usually used for this purpose. The daily dose of glucocorticoids to replace AI has been critically revised over the last 40 years. Based on radioisotope evaluation of endogenous cortisol production, former studies considered as physiological 30 mg of hydrocortisone [45]. Modern techniques measuring cortisol production rates suggest that the mean total daily production by adrenal glands is 5–8 mg/m² body surface of cortisol which approximates to a total daily dose of 15-20 mg of hydrocortisone or 18-25 mg of cortisone acetate [46,47]. When the dose was adjusted by body weight (i.e., 0.12 mg/Kg per day), the cortisol profiles were shown to be more physiological as compared to the fixed dose regimens [48].
In most patients with primary AI, mineralcorticoid replacement with fludrocortisone is required to replace the inability of adrenal gland to synthesize aldosterone [30, 40].

Since the adrenals are heavily involved in the hormonal response to stress, the glucocorticoid replacement dose must be increased by two-three times in stressful conditions, such as fever, trauma, surgical interventions or intercurrent illness. In the case of vomiting or diarrhea, glucocorticoids must be administered intramuscularly or intravenously [40].

In mitotane-induced primary AI, patients require supraphysiological glucocorticoid supplementation owing to an increased metabolic clearance rate of glucocorticoids and enhanced production of cortisol-binding globulin induced by this drug [21, 22].

Secondary AI

Replacement therapy of secondary AI had the following peculiarities:

- Mineralcorticoid replacement therapy is not required in patients with secondary AI in whom renin-angiotensin- aldosterone axis is preserved [25, 29].

- Dose of hydrocortisone is often lower in secondary vs. primary AI [49]. The dose for glucocorticoid replacement may also be influenced by the residual ACTH secretion, concomitant therapies and diseases [25,29]. In fact, patients with hypopituitarism under treatment with recombinant human GH and estrogens may need higher glucocorticoid dose as compared to patients in whom GHD and hypogonadism are not replaced. This reflects the inhibitory effects of GH on 11β-hydroxysteroid dehydrogenase type 1 responsible for activation of cortisone in cortisol [25] and the decrease of cortisol bio-availability induced by estrogens [4].

Adrenal Hyperplasia- Congenital

In patients with congenital adrenal hyperplasia, glucocorticoid therapy has the dual purpose to replace cortisol insufficiency and inhibit the compensatory increase of ACTH [30]. Long-acting
glucocorticoids, such as prednisone and dexamethasone, may be used in patients with adrenal hyperplasia with the aim to better control ACTH values and suppress hypersecretion of adrenal hormones upstream the enzymatic defect [30]. Indeed, there are no randomized controlled studies on long-term effects of different types of treatment of adults affected by classic congenital adrenal hyperplasia. An European Society for Paediatric Endocrinology (ESPE) survey found out that 36% of clinicians used hydrocortisone (mean dose 13.75 mg/m²), 14% used prednisolone (4.75 mg/daily) and 33% used dexamethasone (0.5 mg/daily) as treatment in adults with congenital adrenal hyperplasia [50]. Mineralcorticoids are contraindicated in patients with congenital and acquired deficiency of 17α-hydroxylase and C17,20-lyase, since mineralcorticoid synthesis is increased in these clinical conditions [9, 32].

**Adrenal Hyperplasia- Acquired**

As previously mentioned, abiraterone administration mimics pharmacologically the congenital adrenal hyperplasia due to 17α-hydroxylase deficiency. Therefore, abiraterone must be given in combination with glucocorticoids in order to avoid reduction in serum cortisol, the consequent increase in ACTH and the accumulation of steroids with mineralcorticoid properties [51]. However, in mice abiraterone is converted by an enzyme to the more active ∆4-abiraterone, that blocks multiple steroidogenic enzymes with a final more marked adrenal secretion inhibition and no increase in mineralcorticoid production [52]. In this setting, the steroid supplementation would only have the aim of replacing cortisol deficiency. Nevertheless, the endogenous production of ∆4-abiraterone in treated patients is quite variable, and therefore patients under abiraterone treatment are given prednisone at doses of 5 mg in the morning and in the evening to compensate cortisol insufficiency and to prevent ACTH increase [9]. However, although this therapeutic regimen normalizes ACTH secretion preventing the increase in steroids with mineralcorticoid activity, it does not resemble the circadian rhythm of cortisol and the dose of prednisone used for this purpose
is a half to two-fold higher than that required to physiologically replace AI. Recently, a prospective randomized multinational phase II trial was conducted (NCI study number: NCT01867710) in one hundred sixty-four consecutive metastatic prostate cancer patients with asymptomatic, chemotherapy-naïve, castration resistant disease. They were randomized to receive abiraterone in association with prednisone at one of three different dose schedules: 5 mg twice daily (Bis In Die; BID), 5 mg once daily, 2.5 BID, or dexamethasone 0.5 mg once daily. The preliminary results of this study presented as a meeting abstract [53] suspected that during 24 weeks of treatment with Abiraterone, 5 mg prednisone BID and DEX 0.5 mg once daily both adequately controlled mineral corticoid excess induced by abiraterone. Prednisone either 2.5 BID or 5 mg once daily were efficacious but required adequate monitoring, especially for patients with high systolic blood pressure or pre-existing hypertension at baseline. No data are available on the potential side effects of these regimen in this short term study period. No studies have been performed using hydrocortisone or cortisone acetate in addition to abiraterone therapy.

**Clinical consequences of glucocorticoid overtreatment**

Notwithstanding the current use of lower daily doses of glucocorticoids as compared to the past, the conventional therapeutic regimens of AI do not perfectly mimic the circadian rhythm of cortisol secretion resulting in a non-physiological pattern of hormone peaks during the day [6]. This may also be due to the persistent challenges in monitoring treatment; as a matter of fact, there is still no universal agreement on how to perform it. Rousseau et al. suggested that a single point plasma of cortisol over 402 nmol/l as measured at 10.00 a.m may predict over-replacement under standardized conditions of hydrocortisone administration [54]. This finding was not confirmed by others [55]. The use of urinary free cortisol levels is limited by a high inter-individual variability and with this method it is not possible to identify fluctuations of serum cortisol levels throughout the day [56]. Moreover, urinary cortisol values may be impacted by the saturation of cortisol-binding protein that
is influenced by the dose distribution of hydrocortisone replacement therapy [57]. Specifically, urinary cortisol values were lower when hydrocortisone daily dose was fractioned as compared to the single dose administration. More recently, salivary cortisol measurements have been used, but also with this method a high inter-individual variability as well as a poor correlation with plasma measurements is observed [58]. Moreover, measurement of scalp hair cortisol concentrations has been proposed as a tool to evaluate the exposure of patients to hydrocortisone overtreatment over much longer periods of time (months to years) than possible with samples of blood, saliva or urine [59, 60]. Still, many clinicians base dose changes on clinical parameters. Finally, it is almost impossible to biochemically monitor the adequacy of the substitutive regimens with steroid different from hydrocortisone or cortisone acetate.

As a matter of fact, an over-treatment may occur in several patients treated with AI [5]. Patients may not show clinical features of overt hypercortisolism and clinicians traditionally consider such mild glucocorticoid excess to have little clinical relevance. Indeed, during the last years, several studies have provided convincing data that over-replacement of AI may be associated with high risk of cardiovascular and bone complications (Figure 1), impaired QoL and increased mortality. In the following sections we will summarize the evidence on which these assumptions are based.

**Cardiovascular (CV) risk**

Glucocorticoids are known to have permissive activity on vasoactive agents, such as angiotensin II and catecholamines [61]. Moreover, at high doses, glucocorticoids have access to mineralcorticoid receptor in the kidney due to saturation of 11β-hydroxysteroid dehydrogenase type 2 isoenzyme. Therefore, hypertension frequently occurs in patients under long-term treatment with corticosteroids (Figure 1) [62].
Glucocorticoids are also known to affect glucose metabolism [63] (Figure 1). They increase hepatic gluconeogenesis, inhibit peripheral glucose utilization and promote hepatic glycogen synthesis by making substrates available for an acute stress response. Moreover, glucocorticoids inhibit insulin production leading to a pancreatic β-cell dysfunction which may be an important contributing factor to the development of glucose intolerance and diabetes in patients exposed to glucocorticoid excess [63]. Diabetes and glucose intolerance are frequent complications of glucocorticoid excess, even when hypercortisolism is mild and “subclinical” [63].

Glucocorticoids have complex, still not fully elucidated effects on lipid metabolism, including direct and indirect actions on lipolysis, free fatty acid production and turnover, very-low-density lipoproteins synthesis, and fatty accumulation in liver [64] (Figure 1). A positive correlation exists between plasma LDL-cholesterol and endogenous plasma cortisol in healthy men [65]. Five studies, including 6,799 patients, specifically evaluated the effects of conventional glucocorticoid replacement therapy on CV risk in AI patients; 3 studies were retrospective [66-68], one cross-sectional [69] and one prospective [70] [Table 1].

*Primary AI.* Patients with primary AI under conventional treatment showed high cardiovascular risk profile characterized by higher prevalence of central adiposity, impaired glucose tolerance and a trend towards an increased risk of dyslipidemia [71]. Similar findings were observed in patients treated with 3-6 mg daily of prednisolone, whereas a significant improvement of lipid profile was observed when patients were treated with hydrocortisone at doses lower than 30 mg per day [68]. However, there is evidence that other factors, such as genetic background and lifestyle, may influence the cardiovascular risk regardless of corticosteroid doses. In fact, South African patients with primary AI exhibited a more atherogenic lipid profile, despite being exposed to lower daily hydrocortisone doses, in comparison with Swedish adrenal insufficiency patients [69].
In patients with AI under conventional therapeutic regimen, disorders of glucose homeostasis seem to be correlated with the altered circadian rhythm of cortisol more than with the total daily dose [72, 73]. In fact, glucose homeostasis did not change significantly reducing hydrocortisone daily dose but it significantly improved when replacement therapy was performed using the dual-release hydrocortisone with more physiological cortisol profile during the day (see section Future directions). Patients with autoimmune AI may develop type 1 diabetes in the context of autoimmune polyendocrine syndrome type 2; in these cases, glucocorticoid replacement therapy may influence the amount of insulin needed and the glycometabolic control [74].

The effects of glucocorticoid therapy on blood pressure in primary AI are still a matter of uncertainty, since a recent study provided evidence that genetic background more than hydrocortisone dose may influence the risk of hypertension in this clinical setting [69]. However, the observation that systolic and diastolic blood pressure increased after switching from low to high dose of hydrocortisone [70] and improved after switching from conventional to dual-release hydrocortisone therapy [72] suggests that daily exposure to cortisol may influence blood pressure in patients with AI.

**Secondary AI.** Hypopituitarism is a clinical condition characterized by the presence of several traditional and emerging cardiovascular risk factors, that can significantly increase cardiovascular morbidity and mortality. So far most of the studies in hypopituitary patients took into consideration primarily the role of GHD, noticing an alteration not only of lipid profile and blood pressure, but also an increase in pro-inflammatory cytokines [75, 76]. Also in secondary AI the increase in blood pressure due to glucocorticoid over-replacement may lead to an increase in cardiovascular deaths [77]. Indeed, a recent observational study showed higher risk of hyperlipidemia and hypertension in secondary as compared to primary AI and congenital adrenal insufficiency [78]. Moreover, the dose of hydrocortisone was shown to be closely correlated with higher blood pressure [70] and
hydrocortisone doses higher than 20 mg per day were associated with an unfavorable metabolic profile characterized by increased serum levels of total cholesterol, LDL-cholesterol and triglycerides and higher body mass index after adjustment for sex and age [66]. Interestingly, reducing hydrocortisone dose by 50% was accompanied by improvement of body composition and lipid profile [66]. Moreover, patients treated with prednisone or dexamethasone showed worst body composition [66] and higher LDL-cholesterol [68] as compared to patients treated with hydrocortisone.

**Adrenal Hyperplasia.** High prevalence of obesity, diabetes and hyperlipidemia was found in patients with congenital adrenal hyperplasia as compared to control subjects [79, 80]. Moreover, the relative risk of diabetes was higher in congenital adrenal hyperplasia as compared to the other forms of AI [78]. Interestingly, also cardiovascular diseases, such as atrial fibrillation and thromboembolism occurred at increased rates in these patients [80]. Indeed, the inherent hormonal imbalances of hyperandrogenism and glucocorticoid deficiency may be important in the pathophysiology of the increased cardiovascular risk of patients with congenital adrenal hyperplasia. In fact, a strong negative correlation between abdominal adiposity and sex-hormone binding protein was noted and the physiological differences in visceral adiposity between males and females were lost in congenital adrenal hyperplasia [79]. However, an important role may be also exerted by the supraphysiological glucocorticoid replacement, although the retrospective design of the available studies did not allow to clarify the specific impact of glucocorticoid over-replacement on cardiovascular morbidity. In fact, doses of corticosteroids were usually reported only at the time of the study and the cumulative dose during the entire treatment period was not specified. However, it is noteworthy that male patients with congenital adrenal hyperplasia treated with dexamethasone showed higher body mass index than patients receiving hydrocortisone [67], suggesting that the
daily glucocorticoid exposure may have an impact on body composition and then on cardiovascular risk.

An open issue is also whether treatment of congenital adrenal hyperplasia may cause hypertension. One study reported lower blood pressure values in patients with treated congenital adrenal hyperplasia as compared to reference population [67], whereas other studies showed higher risk of hypertension, visceral obesity, atrial fibrillation, venous thrombo-embolism, diabetes and hyperlipidemia in patients with congenital adrenal hyperplasia as compared to control population [78-80]. The low prevalence of hypertension in some experiences may likely reflect the preferential use of hydrocortisone versus long-acting corticosteroids [67].

**Skeletal fragility**

Glucocorticoids exert multiple undesired effects on bone health [81] (Figure 1). The central pathophysiological mechanism of glucocorticoid-induced osteoporosis is the suppression of bone formation, due to inhibitory effects of glucocorticoids on osteoblast differentiation and function, accounting for chronic impairment of bone quality and disproportionate loss of bone strength in relation to bone mass in this form of secondary osteoporosis [82]. Besides the direct effects on bone cells, glucocorticoids may also have indirect effects mediated by derangements in neuroendocrine signals [83]. The effects of glucocorticoids on GH secretion are worthy to be mentioned since both AI and glucocorticoid excess may impair GH secretion [14, 15]. Interestingly, low circulating levels of glucocorticoids, as they occur in untreated AI, cause a functional impairment of GH secretion which is rapidly reverted by restoring normal cortisol values (“Giustina effect”) [15, 84, 85]. However, when glucocorticoid levels exceed the physiological range, an increase in hypothalamic somatostatin tone may occur with consequent impairment of GH secretion [86-88]. This inhibitory effect on pituitary GH secretion was observed even when the glucocorticoid excess was mild, as in patients with subclinical hypercortisolism [89]. Glucocorticoids may have also effects on sex
hormones production [83]. Specifically, glucocorticoids inhibit the release of gonadotropins with consequent secondary hypogonadism. However, the real impact of GHD and hypogonadism on skeletal fragility in patients with treated AI is still largely unknown since no studies have specifically investigated the incidence and functional relevance of neuroendocrine derangements in untreated and treated AI [86]. However, there is some literature evidence that GHD may influence the effects of glucocorticoid replacement therapy in patients with secondary AI (see below).

Nine studies, including 743 patients, were considered for evaluation of conventional glucocorticoid replacement therapy effects on skeletal health in patients with AI [Table 2]. Seven studies were cross-sectional [90-96] and 2 were prospective [97, 98].

**Primary AI.** Data on skeletal health in AI are inconsistent and even contradictory, with studies reporting low BMD and other reporting normal densitometric values [4,5,18]. Different factors may influence the heterogeneity of BMD results in this clinical setting, such as different study designs and populations, genetic variability, androgen status and type and/or dose of corticosteroids used to replace AI. Interestingly, low BMD values were associated with polymorphism of rs1045642 in the efflux transporter P-glycoprotein, which was shown to cause impaired function of this protein with consequent increment in intracellular cortisol levels and higher sensitivity to glucocorticoid therapy [92]. Moreover, androgen deficiency may influence skeletal health in this clinical setting although higher BMD values in relationship with dehydroepiandrosterone (DHEA) therapy were reported in only one small study [94]. In cross-sectional studies, BMD was shown to be inversely correlated with hydrocortisone daily doses [90, 92] and pathological BMD values were reported mainly in patients treated with more than 30 mg per day of hydrocortisone [92], whereas normal BMD values were found in patients treated with 20 mg per day or lower hydrocortisone doses [94]. Moreover, BMD values at femoral neck and lumbar spine were lower and the rate of osteoporosis was higher in patients treated with prednisolone as compared to those treated with hydrocortisone at equivalent
doses [91, 94]. The skeletal impact of optimization of corticosteroid replacement therapy was investigated by two prospective studies [97, 98]. In the first study performed in a small and heterogeneous population of patients with primary and secondary AI, the decrease of hydrocortisone dose from 30 to 20 mg per day led to a mixed results with some patients improving their BMD and other continuing to lose bone [97]. More consistent results were obtained by the other prospective study in which the decrease in hydrocortisone dose was accompanied by a significant improvement in BMD at lumbar spine and total hip, whereas a further decrease in femoral neck BMD was shown in those patients in whom corticosteroid doses were increased [98].

BMD is not a reliable predictor of fracture risk in patients exposed to glucocorticoid excess [83], similarly to other forms of secondary osteoporosis [99-101]. However, data on fractures in patients treated with glucocorticoids for AI are scanty and somehow controversial. Higher frequency of hip fractures was observed in patients with primary AI but the specific effects of glucocorticoid over-replacement on this outcome was uncertain since the high fracture risk was reported to be highest in the first year after diagnosis of adrenal disease [102]. Prevalence of radiological vertebral fractures was found to be not increased in a small series of patients with primary AI [92], although the study was not sufficiently powered to address this specific end-point.

Secondary AI. Pituitary hormones have direct and indirect effects on bone remodelling, and low bone turnover and decreased BMD are frequently observed in patients with hypopituitarism. There has been evidence that GHD is the main determinant of skeletal fragility in patients with hypopituitarism [99] and replacement therapy of GHD was shown to normalize the fracture risk [103]. In this context, treatment of AI with hydrocortisone doses higher than 28 mg per day was associated with higher prevalence of vertebral fractures in adult males mainly when GHD was not replaced [93], consistently with the physiological concept that in absence of GH glucocorticoids are over-activated at the peripheral tissue level [99].
**Adrenal Hyperplasia.** Adult patients with congenital adrenal hyperplasia showed reduced BMD as compared to primary AI [94] and almost threefold increase in osteopenia/osteoporosis as compared to control subjects [95, 104]. Consistently with the hypothesis that low BMD was caused by glucocorticoid overtreatment, decreased bone formation markers were reported in patients with congenital adrenal insufficiency [95], as well as in those with primary adrenal insufficiency. Interestingly, all patients with osteoporosis were taking prednisolone, whereas those taking hydrocortisone or cortisone acetate showed higher BMD values [95]. Indeed, no correlation between glucocorticoid doses and BMD was observed [96, 104], although the markedly suppressed androgens reported in most of these patients may suggest that supraphysiological doses of corticosteroids may have caused bone loss [104]. High prevalence of clinical fractures was reported in about 30% of women with congenital adrenal hyperplasia in close relationship with the age of patients [104].

The issue of skeletal fragility may be clinically relevant in patients with prostate cancer treated with abiraterone, in whom the detrimental effects of long-acting glucocorticoids used to replace cortisol insufficiency and reduce ACTH increase may be amplified by coexistent drug-induced hypogonadism and possible skeletal localization of cancer cells [81].

**Quality of life (QoL)**

Patients on replacement therapy for AI consistently self-report impairment in QoL by means of specific but also generic self-questionnaires [5, 18, 105]. Patient's Association membership, female gender, older age, presence of other autoimmune or inflammatory comorbidity, lower education and delayed diagnosis of AI, longer disease duration predicted impaired QoL [106-108]. Impaired QoL may occur due to affective and depressive disorders which were shown to occur more frequently in AI [108-110]. Noteworthy, occupational changes due to AI were reported by
40% of interviewed patients and a variable degree of work disability was registered in about 20-30% of patients with AI [108, 111-113]. Sleep disturbances, occurring as effect of disruption in the cortisol rhythm [114], may also play a role in influencing QoL in patients with primary AI [115]. Patients with secondary AI showed more pronounced impairment of QoL and more frequent working disability as compared to patients with primary AI [111], likely reflecting the potential impact of hypopituitarism on these clinical outcomes [116]. Patients with congenital adrenal hyperplasia showed a better QoL as compared primary AI [117]. Indeed, reports of QoL in congenital adrenal hyperplasia are inconsistent since variable results have been provided by the several studies published on this topic [118]. One could argue that the apparently better QoL in patients with congenital adrenal hyperplasia may derive from the fact they have never experienced a time without their disorder [118]. However, it is worthy to be mentioned that some patients with congenital adrenal hyperplasia may refer impaired QoL in relationship with the dose of corticosteroids, use of long-acting formulations and increase adiposity and insulin resistance [118-120].

The impact of replacement regimens on QoL has been specifically investigated by 12 studies including 3,844 patients [Table 3]. Six studies were prospective [121-125], 5 were cross-sectional [119, 120 127-129] and one was retrospective [130]. Indeed, the results were controversial. Some studies did not report any association between corticosteroid doses and QoL [121, 123]. Others, by contrast, reported more pronounced impairment of QoL in patients with primary and secondary AI receiving more than 20-30 mg per day of hydrocortisone as compared to those treated with lower corticosteroid doses [124, 128, 130]. Moreover, an association between high hydrocortisone dose and high prevalence of inadequate personality traits and depression was also observed [129]. On the other hand, two cross-over studies reported an impairment in QoL and pain after decreasing hydrocortisone doses [122, 126] suggesting that some patients may benefit from maintaining high dose of glucocorticoids for replacing AI. However, the results of cross-over studies may be
influenced by carryover effect of glucocorticoids and also by eventual slow adaption of peripheral tissue sensitivity to rapid changes in drug doses. As a matter of fact, the improvement of self-reported well-being in patients treated with four-dose regimen of hydrocortisone [125] and in those switching from conventional therapeutic regimens to dual-release hydrocortisone [72,73] may suggest that a more physiological cortisol exposure may have some benefits on QoL, such as demonstrated for other clinical outcomes.

**Mortality**

*Primary AI.* In population-based studies, the relative risk of death was increased by more than twofold in young adult patients with primary AI under replacement therapy in relationship with cardiovascular, malignant and infectious diseases, particularly when diabetes was coexistent [131]. Noteworthy, most patients received high doses of cortisone acetate (i.e., higher than 37.5 mg per day) [131]. Another retrospective study showed increased mortality in patients (median aged 57; 0-85 years) with autoimmune polyendocrine syndrome type 1, characterized by the coexistence of AI, hypoparathyroidism and chronic mucocutaneous candidiasis [132]. When the survival analysis was performed by a prospective approach, no major increase in mortality rate was observed among patients with AI as compared to the general population, with the exception of young patients below 40 years of age in whom a twofold increase of standardized mortality ratio was shown mainly related to infections and sudden death besides acute adrenal crisis [133].

*Secondary AI.* Mortality is increased in patients with hypopituitarism, in relationship with untreated GHD, untreated hypogonadism and (over-) treated secondary AI [77, 134, 135]. Moreover, the risk of death from infectious diseases was 1.6-fold higher in patients with ACTH deficiency than in those without ACTH deficiency [136] in close relationship with development of acute adrenal crisis in response to acute stress and intercurrent illness [137]. Indeed, high incidence (i.e., 8.3 per 100
patient-years) of adrenal crisis was observed in patients with chronic AI receiving standard replacement therapy, even if well educated to adjust glucocorticoid doses during critical illness [138]. Noteworthy, about half of the sudden unexpected deaths occurring in patients with secondary AI was related to adrenal crises [139].

In patients treated for acromegaly, those with AI were at increased risk of premature death when treated with hydrocortisone at a daily dose higher than 25 mg compared to those receiving lower doses [7].

**Adrenal hyperplasia.** Mortality has been reported to be high in patients (median age of patients 26, range 0-92 years; median age of death 44.1; range 0-91 years) with congenital adrenal hyperplasia, although the impact of glucocorticoid overtreatment on this outcome is still uncertain [140].

In the pivotal trial [33], the combination therapy abiraterone and prednisone led to a reduction in mortality compared to treatment with prednisone alone. Indeed, the specific role of glucocorticoid treatment on mortality of patients with prostate cancer under abiraterone treatment is still unknown. It is worth mentioning that glucocorticoids were hypothesized to favor progression of prostate cancer by reactivating adrenal receptor signaling in cancer cells exposed to androgen receptor blockade [141]. On the other hand, glucocorticoids may have beneficial effects on symptoms of patients with prostate cancer [141].

**Conclusions and future directions**

Conventional hydrocortisone replacement regimens in the management of AI cannot provide the physiological rhythm of cortisol release and result in temporary over- or under-replacement [142], although most of evidence on the unfavorable outcomes of conventional glucocorticoid regimens derives from retrospective and cross-sectional studies not allowing to reliably definitive specific recommendations. However, over the last years, pharmacologic research has developed
new hydrocortisone formulations to potentially improve treatment of AI [43, 143, 144], although their relative high cost and the limited availability in some countries do not yet permit the universal use of these drugs for treatment of AI. Interestingly, the more physiological serum cortisol resulting from this innovative treatment profile was shown to be accompanied by an improvement in several clinical outcomes of patients with primary and secondary AI [72, 73, 143-147]. In fact, the use of dual-release hydrocortisone was associated with reductions in body weight, glycated hemoglobin, and blood pressure and improvements in bone formation markers and QoL as compared to conventional therapeutic regimen either in head-to-head studies [72, 147] or in prospective evaluations performed in patients who were switched from conventional hydrocortisone replacement treatment to the dual-release hydrocortisone formulation [72, 73]. It is noteworthy that type 1 diabetes mellitus patients reduced their insulin requirement during dual-release hydrocortisone treatment [72]. Interestingly, the daily doses of conventional regimen and dual-release hydrocortisone were similar, suggesting that for anthropometric and metabolic parameters, the improvement in serum cortisol profile was more important than reducing daily drug dose to prevent glucocorticoid over-treatment.

Congenital or acquired adrenal hyperplasia is an unique clinical model to investigate the effects of overreplacement therapy with glucocorticoids on different clinical outcomes since glucocorticoids are used for both hormonal replacement and suppression purposes [148]. In a recent study, treatment with modified release hydrocortisone (i.e., Chronocort) appeared to be superior to conventional glucocorticoid therapy in controlling androgen synthesis in patients with congenital adrenal hyperplasia [144], but the potential impact of this treatment on the clinical outcomes related to glucocorticoid over-replacement is still unknown.

Indeed, future randomized-blinded studies are needed to definitively confirm the potential advantages of the new formulations of hydrocortisone as compared to the conventional therapies in the different forms of hypoadrenalism. Moreover, studies will need to be powered to evaluate hard
clinical end-points, such as major cardiovascular events, fragility fractures and mortality. In fact, the study design should take into account the peculiarities of clinical outcomes related to glucocorticoid over-replacement, such as the development of fragility fractures regardless of BMD values [83] and the predominant occurrence of hyperglycemia during the late afternoon or evening [63]. Moreover, in evaluating QoL disease-specific questionnaires should be used and the effects of glucocorticoid over-treatment should be differentiated by those of comorbidities.

In the specific condition of abiraterone-induced AI, there are some peculiar aspects that need to be pointed out. Firstly, based on data provided by AI and congenital adrenal hyperplasia models, the currently used therapeutic regimen to suppress ACTH (i.e. 10 mg of prednisone) provides a supraphysiologic glucocorticoid exposure. Abiraterone is currently administered in patients with castration resistant prostate cancer that have a relatively limited survival perspective; therefore, the long-term effects of relatively excessive glucocorticoid exposure may be not particularly relevant. However, this risk becomes more clinically significant with the use of this drug in less advanced forms of prostate cancer with increased chances of long-term survival. From this point of view, long term results of randomized clinical studies will show if prednisone supplementation at reduced doses (5 mg/daily) may improve the tolerability [53]. Probably, alternative glucocorticoids such as hydrocortisone to replace abiraterone-induced AI could be of value and deserve to be tested in the future. Secondly, it is conceivable that complete suppression of mineralcorticoid hypersecretion may likely not be needed in all patients since a residual synthesis of these hormones may be useful to compensate the cortisol insufficiency induced by abiraterone. On the other hand, the possible mineralcorticoid excess syndrome can be managed by mineralcorticoid receptor antagonists, as eplerenone [149]. However, eplerenone can bind androgen receptors and can exert a stimulatory effect on prostate cancer growth, thus antagonizing the anti-androgen efficacy [150]. Interestingly, novel non-steroidal compounds are currently in clinical development, and, due to their chemical structure, may not bind androgen receptors [151]. In addition, amiloride selectively reduces the
aldosterone-sensitive Na⁺/K⁺ exchange, leading to increased urinary Na⁺ excretion with relative K⁺ sparing effects. Due to its non steroidal chemical structure and the different mechanism of action, this drug do not interact with the androgen receptor and therefore it can be used in association with abiraterone. Preliminary data showed that the association of amiloride and hydrochlorothiazide is efficacious in the management of mineral corticoid excess syndrome induced by abiraterone [152].

Finally, during mitotane therapy for the management of patients with adrenocortical carcinoma supportive treatment that includes high-dose hydrocortisone replacement therapy is invariably needed; however, since the patients under this therapy frequently suffer from fatigue that is only partially due to hypocortisolism but improve with the increase of cortisone supplementation they are at risk of supraphysiologic glucocorticoid exposure. This issue is particularly relevant when mitotane is administered in the adjuvant setting in which the drug is recommended to be continued for a minimum of 2 years although there are no data regarding the optimal duration of this treatment [153]. Studies testing the long-term effects of steroid supplementation with conventional and new hydrocortisone formulations during adjuvant mitotane are needed in the future [154].
Declaration of interest:

G. Mazziotti, S. Frara, E. Roca, P. Mortini, A. Berruti declare that there is no conflict of interest that could be perceived as prejudicing the impartially of the research reported. A.M. Formenti received consultant fees from Shire. A. Giustina is a consultant for Astellas, Ipsen, Novartis, Pfizer, Shire.

Funding: This research was partially supported by G.I.O.S.E.G. (Glucocorticoid-induced osteoporosis and Skeletal Endocrinology Group).
References


Legend to Figure 1: Schematic representation of complications of adrenal insufficiency overtreatment and related mechanisms. GHD, growth hormone deficiency; VLDL, very low density lipoproteins; LDL, low density lipoproteins.
Table 1: Effects of conventional glucocorticoid replacement regimens on cardiovascular risk in patients with adrenal insufficiency (AI).

<table>
<thead>
<tr>
<th>Author, year</th>
<th>Pts.</th>
<th>PAI/SAI/CAH</th>
<th>Study design</th>
<th>Main results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Filipsson, 2006&lt;sup&gt;66&lt;/sup&gt;</td>
<td>2424</td>
<td>0/2424/0</td>
<td>Retrospective, cross-sectional</td>
<td>↑ W/H (PDN vs. HC/CA); ↑ T-COL, LDL-C, TG (high HC dose vs. low HC dose)</td>
</tr>
<tr>
<td>Ross, 2014&lt;sup&gt;69&lt;/sup&gt;</td>
<td>110</td>
<td>110/0/0</td>
<td>Cross-sectional</td>
<td>↓ LDL-C, Tg; ↑ HDL-C (high HC dose vs. low HC dose)</td>
</tr>
<tr>
<td>Bouvattier, 2015&lt;sup&gt;67&lt;/sup&gt;</td>
<td>219</td>
<td>0/0/219</td>
<td>Retrospective, cross-sectional</td>
<td>↑ BMI (PDN vs. HC)</td>
</tr>
<tr>
<td>Werumeus Buning, 2016&lt;sup&gt;70&lt;/sup&gt;</td>
<td>47</td>
<td>0/47/0</td>
<td>Prospective, randomized</td>
<td>↑ SBP and DBP (high HC dose vs. low HC dose)</td>
</tr>
<tr>
<td>Quinkler, 2017&lt;sup&gt;68&lt;/sup&gt;</td>
<td>188</td>
<td>75/113/0</td>
<td>Retrospective, cross-sectional</td>
<td>↑ LDL-C (PDN vs. HC)</td>
</tr>
</tbody>
</table>

Pts., patients; PAI, primary adrenal insufficiency; SAI, secondary adrenal insufficiency; CAH, congenital adrenal hyperplasia; W/H, waist/hip ratio; PDN, prednisolone; HC, hydrocortisone; CA, cortisone acetate; T-COL, total cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure.
Table 2: Effects of conventional glucocorticoid therapeutic regimens on skeletal health in patients with adrenal insufficiency (AI).

<table>
<thead>
<tr>
<th>Author, year</th>
<th>Pts.</th>
<th>PAI/SAI/CAH</th>
<th>Study design</th>
<th>Main results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zelissen, 1994&lt;sup&gt;90&lt;/sup&gt;</td>
<td>91</td>
<td>91/0/0</td>
<td>Cross-sectional</td>
<td>↓ LS BMD (in relationship with HC dose in men)</td>
</tr>
<tr>
<td>Peacey, 1999&lt;sup&gt;97&lt;/sup&gt;</td>
<td>12</td>
<td>6/6/0</td>
<td>Prospective</td>
<td>↓ or ↑ LS BMD after decreasing HC dose</td>
</tr>
<tr>
<td>Jodar, 2003&lt;sup&gt;91&lt;/sup&gt;</td>
<td>25</td>
<td>25/0/0</td>
<td>Cross-sectional</td>
<td>↑ osteoporosis (PDN vs. HC)</td>
</tr>
<tr>
<td>Løvås, 2009&lt;sup&gt;92&lt;/sup&gt;</td>
<td>292</td>
<td>292/0/0</td>
<td>Cross-sectional</td>
<td>↓ FN and LS BMD (PAI vs. reference population, in relationship with HC dose); ↔ VFs.</td>
</tr>
<tr>
<td>Mazziotti, 2010&lt;sup&gt;93&lt;/sup&gt;</td>
<td>41</td>
<td>0/41/0</td>
<td>Cross-sectional</td>
<td>↑ VFs (untreated GHD and over-treated SAI vs. treated GHD)</td>
</tr>
<tr>
<td>Koetz, 2012&lt;sup&gt;94&lt;/sup&gt;</td>
<td>122</td>
<td>81/0/41</td>
<td>Cross-sectional</td>
<td>↓ bone turnover markers, LS and FN BMD (PDN vs. HC),</td>
</tr>
<tr>
<td>Falhammar, 2013&lt;sup&gt;95&lt;/sup&gt;</td>
<td>32</td>
<td>0/0/32</td>
<td>Cross-sectional</td>
<td>↑ osteoporosis (PDN vs. HC).</td>
</tr>
<tr>
<td>Ceccato, 2016&lt;sup&gt;96&lt;/sup&gt;</td>
<td>38</td>
<td>0/0/38</td>
<td>Cross-sectional</td>
<td>↓ FN BMD (CAH vs. controls); no correlation with GC dose.</td>
</tr>
<tr>
<td>Schulz, 2016&lt;sup&gt;97&lt;/sup&gt;</td>
<td>90</td>
<td>57/0/33</td>
<td>Prospective</td>
<td>↑ TH and LS BMD after decreasing HC dose; ↓ FN BMD after increasing HC dose.</td>
</tr>
</tbody>
</table>

Pts., patients; PAI, primary adrenal insufficiency; SAI, secondary adrenal insufficiency; CAH, congenital adrenal hyperplasia; LS, lumbar spine; BMD, lumbar spine bone mineral density; PDN, prednisolone; HC, hydrocortisone; FN, femoral neck; VFs, vertebral fractures; GHD, growth hormone deficiency; GC, glucocorticoid; TH, total hip.
Table 3: Effects of conventional glucocorticoid replacement regimens on Quality of life (QoL) in patients with adrenal insufficiency (AI).

<table>
<thead>
<tr>
<th>Author, year</th>
<th>Pts.</th>
<th>PAI/SAI/CAH</th>
<th>Study design</th>
<th>Main clinical outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wichers, 1999</td>
<td>9</td>
<td>0/9/0</td>
<td>Prospective, randomized</td>
<td>↔ QoL (high HC dose vs. low HC dose)</td>
</tr>
<tr>
<td>Alonso, 2004</td>
<td>12</td>
<td>12/0/0</td>
<td>Prospective</td>
<td>↑ QoL (high HC dose vs. low HC dose)</td>
</tr>
<tr>
<td>Bleicken, 2008</td>
<td>427</td>
<td>232/195/0</td>
<td>Cross-sectional</td>
<td>↔ QoL (PDN vs. HC and CA)</td>
</tr>
<tr>
<td>Bleicken, 2010</td>
<td>334</td>
<td>194/140/0</td>
<td>Cross-sectional</td>
<td>↓ QoL (high HC dose vs. low HC dose)</td>
</tr>
<tr>
<td>Behan, 2011</td>
<td>10</td>
<td>0/10/0</td>
<td>Prospective, randomized</td>
<td>↔ QoL (high HC dose vs. low HC dose)</td>
</tr>
<tr>
<td>Benson, 2012</td>
<td>18</td>
<td>0/18/0</td>
<td>Prospective, randomized</td>
<td>↓ QoL (high HC dose vs. low HC dose)</td>
</tr>
<tr>
<td>Ekman, 2012</td>
<td>15</td>
<td>15/0/0</td>
<td>Prospective, randomized</td>
<td>↑ QoL (4 doses of HC vs. 2 doses of HC)</td>
</tr>
<tr>
<td>Han, 2013</td>
<td>151</td>
<td>0/0/151</td>
<td>Cross-sectional</td>
<td>↓ QoL (PDN/DXA vs. HC)</td>
</tr>
<tr>
<td>Falhammar, 2014</td>
<td>30</td>
<td>0/0/30</td>
<td>Cross-sectional</td>
<td>↓ QoL (overtreated vs. poorly controlled and controls)</td>
</tr>
<tr>
<td>Ragnarsson, 2014</td>
<td>2737</td>
<td>0/2737/0</td>
<td>Retrospective, longitudinal</td>
<td>↓ QoL (high HC dose vs. low HC dose)</td>
</tr>
<tr>
<td>Tiemensma, 2014</td>
<td>54</td>
<td>54/0/0</td>
<td>Cross-sectional</td>
<td>↑ inadequate personality traits and depression (high dose HC vs. low dose HC)</td>
</tr>
<tr>
<td>Werumeus Buning, 2016</td>
<td>47</td>
<td>0/47/0</td>
<td>Prospective, randomized,</td>
<td>↑ QoL (high HC dose vs. low HC dose)</td>
</tr>
</tbody>
</table>

Pts., patients; PAI, primary adrenal insufficiency; SAI, secondary adrenal insufficiency; CAH, congenital adrenal hyperplasia; PDN, prednisolone; HC, hydrocortisone; CA, cortisone acetate.
Schematic representation of complications of adrenal insufficiency overtreatment and related mechanisms.

Purple dot: hypothalamus; yellow dot: pituitary gland; orange dot: skeleton; blue dot: cardiovascular system; adrenal glands in red. Color gradients in circles express increased severity of complications with greater degree of overtreatment. GHD, growth hormone deficiency; VLDL, very low density lipoproteins; LDL, low density lipoproteins.